Ovarian Cancer | Specialty

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

Dr. O'Malley on Maintenance Rucaparib in Non-BRCA HRR-Mutated Ovarian Cancer

April 9th 2020

David O’Malley, MD, discusses the rationale to evaluate the clinical benefit of rucaparib maintenance treatment following disease progression in a subgroup of patients with ovarian cancer whose disease is associated with a mutation in a non-BRCA homologous recombination gene in the phase III ARIEL3 trial in ovarian cancer.

Pazopanib Plus Oral Cyclophosphamide Shows Benefit in Platinum-Resistant Epithelial Ovarian Cancer

April 9th 2020

Pazopanib plus oral cyclophosphamide is a well-tolerated regimen that has clinically relevant benefit in patients with platinum-resistant or -refractory epithelial ovarian cancer, according to results from a retrospective study published in the Journal of Clinical Oncology.

Dr. Comerci on the Use of Laparoscopy in Ovarian Cancer

April 9th 2020

John T. Comerci, MD, associate professor, University of Pittsburgh School of Medicine, and director of Gynecologic Oncology, University of Pittsburgh Medical Center Passavant Hospital, discusses the use of laparoscopy in ovarian cancer.

Olaparib/Bevacizumab as Frontline Maintenance Improves PFS in Ovarian Cancer, Regardless of Timing of Surgery, Disease Status

April 8th 2020

The combination of olaparib and bevacizumab was found to improve progression-free survival outcomes versus bevacizumab alone as a frontline maintenance treatment in patients with newly diagnosed advanced high-grade serous ovarian cancer, regardless of the timing of surgery or residual disease status after surgery.

Niraparib/Bevacizumab Combo as Frontline Maintenance Shows Promise in Advanced Ovarian Cancer

April 8th 2020

The combination of niraparib and bevacizumab as a frontline maintenance therapy was found to have impressive clinical activity in patients with advanced ovarian cancer who had a complete or partial response to frontline platinum-based chemotherapy plus bevacizumab.

Dr. Boisen on Scoring System for Optimal Debulking in Ovarian Cancer

April 8th 2020

Michelle M. Boisen, MD, discusses the scoring system for optimal debulking in ovarian cancer.

Dr. Cosgrove on the Utilization of PARP Inhibition in Ovarian Cancer

April 8th 2020

Casey M. Cosgrove, MD, discusses the utilization of PARP inhibition in ovarian cancer.

Trametinib Boosts PFS and Response Rates in Low-Grade Ovarian Cancer

April 7th 2020

Trametinib monotherapy has emerged as a new treatment option for women with recurrent low-grade serous ovarian cancers based on improvements in survival outcomes and response rates demonstrated in a phase II/III study.

Dr. Boisen on Selecting Patients for Surgery Versus Neoadjuvant Chemotherapy in Ovarian Cancer

April 7th 2020

Michelle M. Boisen, MD, discusses criteria for selecting patients with ovarian cancer for upfront surgery versus neoadjuvant chemotherapy.

Analysis Pinpoints Veliparib Antitumor Activity in Ovarian Cancer

April 6th 2020

Adding veliparib to frontline induction chemotherapy increased complete and CA-125 responses compared with chemotherapy alone in patients with high-grade serous ovarian cancer, according to an exploratory analysis of the phase III VELIA trial.

Dr. Chase on Niraparib as Frontline Maintenance Therapy in Ovarian Cancer

April 4th 2020

Dana Chase, MD, discusses niraparib as frontline maintenance therapy in ovarian cancer.

Rucaparib Improves Postprogression Outcomes in Non-BRCA HRR Mutated Ovarian Cancer

April 3rd 2020

Rucaparib was associated with superior outcomes among women with ovarian cancer harboring a non-BRCA homologous recombination repair gene mutation compared with placebo, according to an analysis of specimens collected in the phase III ARIEL3 trial (NCT01968213).

Dr. Olawaiye on the Role of Surgery in Newly Diagnosed Ovarian Cancer

April 3rd 2020

Alexander B. Olawaiye, MD, discusses the role of surgery in women with newly diagnosed ovarian cancer.

Navicixizumab Combo Shows Benefit in Heavily Pretreated Ovarian Cancer

April 3rd 2020

The anti-DLL4/VEGF bispecific antibody navicixizumab showed promising clinical activity when used in combination with paclitaxel in heavily pretreated patients with platinum-resistant ovarian cancer.

Dr. Moore on Early-Phase Data With Mirvetuximab Soravtansine in Ovarian Cancer

April 3rd 2020

Kathleen Moore, MD, discusses the early phase data that led to the development of the phase III FORWARD I/ GOG 3011 trial in ovarian cancer.

Frontline Maintenance Vigil Immunotherapy Improves RFS in Ovarian Cancer

April 3rd 2020

Frontline maintenance treatment with Vigil immunotherapy demonstrated an improvement in relapse-free survival compared with placebo in patients with stage III/IV ovarian cancer, especially in those with BRCA1/2 wild-type disease.

Dr. Swisher on How the VELIA Trial Stands Out in Ovarian Cancer Research

April 2nd 2020

Elizabeth M. Swisher, MD, discusses how the phase III VELIA/GOG-3005 trial compares with other trials examining up-front maintenance therapy in ovarian cancer.

Veliparib Improves PFS in BRCA Wild-Type Ovarian Cancer, Regardless of HRD Status

April 2nd 2020

Veliparib plus chemotherapy extended progression-free survival for BRCA wild-type patients with high-grade serous carcinoma.

Anetumab Ravtansine Shows Promise in Mesothelin-Expressing Solid Tumors

April 2nd 2020

The investigational antibody-drug conjugate anetumab ravtansine showed promising antitumor activity in heavily pretreated patients with mesothelin-expressing solid tumors.

VB-111 Hits Milestone in Phase III Platinum-Resistant Ovarian Cancer Trial

March 27th 2020

An independent panel determined that the investigational agent VB-111 met the interim prespecified efficacy criterion in the phase III OVAL study in patients with platinum-resistant ovarian cancer, and that the trial should continue without modification.